281 |
The effect of bacterial and host proteinases on defence molecules in the cystic fibrosis respiratory tractEinarsson, Gisli Geir January 2009 (has links)
No description available.
|
282 |
Cardiac and Neurohumoral Abnormalities in Systemic SclerosisDonnelly, R. January 2010 (has links)
No description available.
|
283 |
Investigating the expression and secretion of matrix metalloproteinases by inflammatory and parenchymal lung cells in acute lung injuryEdwards, A. J. P. January 2012 (has links)
No description available.
|
284 |
Impact of different CFTR Mutations on Airway Epithelium FunctionWilliams, M. T. S. January 2010 (has links)
No description available.
|
285 |
Human respiratory syncytial virus F protein-induced immunosuppression : structures, mechanisms and novel vaccinesQuinn, Caroline Frances January 2013 (has links)
Respiratory syncytial virus (RSV) is a major cause of morbidity and mortality in humans. It repeatedly infects throughout life, suggesting induction of poor memory immune responses. The RSV F protein is a highly conserved antigen that was studied extensively as a vaccine both in animal models and clinical trials but has so far failed in humans. Interestingly. evidence suggested that RSV F blocks proliferation of PHA-stimulated human PBMCs in a contact-dependent and species-specific manner. Specifically, HRSV F preferentially inhibited human PBLs, while bovine RSV F preferentially inhibited bovine PBLs. We aligned multiple strains of human and bovine RSV to identify 8 species-specific residues. We hypothesized that replacing the 8 HRSV F residues with their bovine counterparts would not alter the antigenic or immunogenic structure of HRSV F, while removing the capacity of HRSV F to block human PBL proliferation. Using site-directed mutagenesis, we generated a recombinant HRSV F protein (rHRSV Fmut8) comprising the 8 bovine residues. rHRSV Fmut8 was shown to retain reactivity when tested with a panel of RSV F-specific MAbs, confirming that the antigenic structure was preserved. We subsequently generated and characterised a recombinant Sendai virus efficiently expressing our mutated HRSV F (rSeV/RSV Fmut8), found to be functional and antigenically intact. S.eV (mwine PIVI) was chosen as a vector, as it is immunogenic but non-pathogenic in humans, has vaccine potential against human parainfluenza virus type I (HPrv 1) and can be easily manipulated by reverse genetics. Following intra-nasal administration to BALB/c mice, rSeV/RSV Fmut8 induced protective immunity against RSV challenge. Human PBMC proliferation block experiments revealed that HRSV efficiently blocks inhibition, in which RSV F plays a role. If confirmed, abrogation of the human PBL proliferation block combined with its protective efficacy in vivo, suggests that rSeV/RSV Fmut8 will constitute a very interesting and novel RSV vaccine candidate.
|
286 |
A comprehensive assessment of funtional outcomes and their impact on the quality of life in surgically treated oral and oropharyngeal cancer patientsDwivedi, Raghav Chandra January 2010 (has links)
No description available.
|
287 |
Clinical trials to investigate the effect of breathing exercises on asthma controlCooper, Susan Elizabeth January 2010 (has links)
No description available.
|
288 |
Studies into mucin and its regulation in pathogenesis of otitis media with effusionGuo, Li January 2009 (has links)
No description available.
|
289 |
Consequences of mild sensorineural hearing loss for listening and learning in childrenMillward, Kerri E. January 2009 (has links)
No description available.
|
290 |
The role of TNFa and IFNy on CXCL10 regulation and beta-2 agonist inhibition in human airway smooth muscle cellsJindarat, Sarawut January 2009 (has links)
No description available.
|
Page generated in 0.0217 seconds